3. Lin H, Jiang S. Combined pulmonary fibrosis and emphysema (CPFE): an entity different from emphysema or pulmonary fibrosis alone. J Thorac Dis, 2015, 7(4): 767-779.
[2]
7. Alarcon-Segovia D, Cardiel MH. Comparison between 3 diagnostic criteria for mixed connective tissue disease. Study of 593 patients. The Journal of rheumatology 1989, 16(3): 328-334.
[3]
11. Cottin V. The impact of emphysema in pulmonary fibrosis. European respiratory review : an official journal of the European Respiratory Society 2013, 22(128): 153-157.
[4]
14. Nair A, Hansell DM. High-resolution computed tomography features of smoking-related interstitial lung disease. Seminars in ultrasound, CT, and MR 2014, 35(1): 59-71.
[5]
15. Ryerson CJ, Hartman T, Elicker BM, et al. Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis. Chest 2013, 144(1): 234-240.
[6]
16. Kitaguchi Y, Fujimoto K, Hayashi R, et al. Annual changes in pulmonary function in combined pulmonary fibrosis and emphysema: over a 5-year follow-up. Respiratory medicine 2013, 107(12): 1986-1992.
[7]
18. Akagi T, Matsumoto T, Harada T, et al. Coexistent emphysema delays the decrease of vital capacity in idiopathic pulmonary fibrosis. Respiratory medicine 2009, 103(8): 1209-1215.
[8]
19. Cottin V, Le Pavec J, Prevot G, et al. Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. The European respiratory journal 2010, 35(1): 105-111.
[9]
1. Cottin V, Nunes H, Brillet PY, et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity.Eur Respir J, 2005, 26(4): 586-593.
[10]
2. Jankowich MD, Rounds SI. Combined pulmonary fibrosis and emphysema syndrome: a review. Chest 2012, 141(1): 222-231.
[11]
4. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum, 1988, 31(3): 315-324.
[12]
5. Troyanov Y, Targoff IN, Tremblay JL, et al. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine 2005, 84(4): 231-249.
[13]
6. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Annals of the rheumatic diseases 2002, 61(6): 554-558.
[14]
8. Cottin V, Cordier JF. Combined pulmonary fibrosis and emphysema in connective tissue disease. Current opinion in pulmonary medicine 2012, 18(5): 418-427.
[15]
9. Cottin V, Nunes H, Mouthon L, et al. Combined pulmonary fibrosis and emphysema syndrome in connective tissue disease. Arthritis and rheumatism 2011, 63(1): 295-304.
[16]
10. Fairweather D, Frisancho-Kiss S, Rose NR. Sex Differences in Autoimmune Disease from a Pathological Perspective. The American Journal of Pathology 2008, 173(3): 600-609.
[17]
12. Smith BM, Austin JH, Newell JD, Jr., et al. Pulmonary emphysema subtypes on computed tomography: the MESA COPD study. The American journal of medicine 2014, 127(1): 94 e97-23.
[18]
13. Kitaguchi Y, Fujimoto K, Hanaoka M, et al. Clinical characteristics of combined pulmonary fibrosis and emphysema. Respirology (Carlton, Vic) 2010, 15(2): 265-271.
[19]
17. Washko GR, Hunninghake GM, Fernandez IE, et al. Lung Volumes and Emphysema in Smokers with Interstitial Lung Abnormalities. New England Journal of Medicine 2011, 364(10): 897-906.
[20]
20. Kurashima K, Takayanagi N, Tsuchiya N, et al. The effect of emphysema on lung function and survival in patients with idiopathic pulmonary fibrosis. Respirology (Carlton, Vic) 2010, 15(5): 843-848.
[21]
21. Mejia M, Carrillo G, Rojas-Serrano J, et al. Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest 2009, 136(1): 10-15.
[22]
22. Jankowich MD, Rounds S. Combined pulmonary fibrosis and emphysema alters physiology but has similar mortality to pulmonary fibrosis without emphysema. Lung 2010, 188(5): 365-373.
